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Recent advances in genetics have yielded an unprecedented number of loci associated with disease and are beginning 
to yield mechanistic insight, such as with the IRX3/5 associa-
tion with body mass index, which revealed brown adipose as an 
important regulator of body weight.1 Genetic variation underly-
ing molecular phenotypes, such as proteins and transcript expres-
sion levels, can be important tools in constructing the effects of 
genetic variations into pathways, ultimately resulting in physi-
ological understanding of diseases.2 Protein levels, in particular, 
may be more informative for understanding disease because there 
is often a poor correlation between transcript and protein levels.3 
Several previous studies4–6 have systematically identified genetic 
variations associated with protein levels and isoforms (protein 
quantitative trait loci [pQTLs]). Although most studies have 
focused on common variation (minor allele frequency ≥5%), rare 
variants, which can show strong loss of function effects, can be 
useful in understanding causality and pinpointing drug targets, 
such as deletion mutations in PSCK9 that abolish the PSCK9 
protein and reduce low-density lipoprotein cholesterol levels.7 
Systematic screening for rare variation influencing a wide 
variety of proteins, however, has not yet been performed.
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Genetic variation is also useful in identifying causal rela-
tionship between biomarkers and diseases using tools such as 
Background—Genetic variation can be used to study causal relationships between biomarkers and diseases. Here, we 
identify new common and rare genetic variants associated with cardiovascular-related protein levels (protein quantitative 
trait loci [pQTLs]). We functionally annotate these pQTLs, predict and experimentally confirm a novel molecular 
interaction, and determine which pQTLs are associated with diseases and physiological phenotypes.
Methods and Results—As part of a larger case–control study of venous thromboembolism, serum levels of 51 proteins 
implicated in cardiovascular diseases were measured in 330 individuals from the Tromsø Study. Exonic genetic variation 
near each protein’s respective gene (cis) was identified using sequencing and arrays. Using single site and gene-based tests, 
we identified 27 genetic associations between pQTLs and the serum levels of 20 proteins: 14 associated with common 
variation in cis, of which 6 are novel (ie, not previously reported); 7 associations with rare variants in cis, of which 4 
are novel; and 6 associations in trans. Of the 20 proteins, 15 were associated with single sites and 7 with rare variants. 
cis-pQTLs for kallikrein and F12 also show trans associations for proteins (uPAR, kininogen) known to be cleaved by 
kallikrein and with NTproBNP. We experimentally demonstrate that kallikrein can cleave proBNP (NTproBNP precursor) 
in vitro. Nine of the pQTLs have previously identified associations with 17 disease and physiological phenotypes.
Conclusions—We have identified cis and trans genetic variation associated with the serum levels of 20 proteins and utilized 
these pQTLs to study molecular mechanisms underlying disease and physiological phenotypes.  (Circ Cardiovasc Genet. 
2016;9:375-383. DOI: 10.1161/CIRCGENETICS.115.001327.)
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Mendelian randomization8 and could be used to ascertain how 
risk factors differentially affect various diseases, as well as 
trace causal pathways between risk loci and disease. We are 
investigating risk factors for cardiovascular diseases, includ-
ing myocardial infarction (MI) and venous thromboembolism 
(VTE) in the Tromsø Study,9 a longitudinal prospective cohort 
study. We previously assayed 51 cardiovascular-related pro-
teins in 419 first-ever MI cases and 398 controls in serum col-
lected years before the MI event.10 Of the proteins measured, 
17 were predictors for MI when considered individually after 
adjusting for traditional risk factors. Genetic variation associ-
ated with these protein levels could be used to study underly-
ing mechanisms of cardiovascular diseases.
Here, using whole exome sequencing data and 
HumanCoreExome BeadChips, we investigate whether genetic 
variants are associated with the serum levels of the same 51 
cardiovascular-related proteins in 330 individuals chosen from 
the Tromsø Study because they did or did not go on to develop 
VTE during the 18 years of follow-up (mean time to VTE of 9 
years). The serum samples were collected at study entry enabling 
us to identify pQTLs associated with baseline protein levels. We 
perform both common and rare variation association analyses to 
identify cis-pQTLs. Further characterization of the cis-pQTLs to 
determine whether they also act as trans-pQTLs with any of the 
other 51 cardiovascular-related proteins, recapitulated well-estab-
lished physiological relationships between F12, kallikrein, uPAR, 
kininogen, and a recent genetic association with NTproBNP. We 
experimentally confirmed an inferred physiological interaction 
from the trans-pQTLs by showing that kallikrein cleaves proBNP 
in vitro. We then examine genetic associations from genome-wide 
association studies on coronary artery disease (CAD) and VTE, as 




The Tromsø Study is a prospective, single-site, cohort study of the 
inhabitants of Tromsø, Norway. In 1994 to 1995, 27 158 individuals 
filled out epidemiological surveys and donated (nonfasting) blood to 
the National CONOR Biobank.9 These individuals were followed until 
2013, with repeated surveys and identified in national registries that 
report various diseases and causes of death. In 2013, we identified 
individuals who, between 1995 and 2013, had had an incident of VTE 
or death due to VTE, regardless of other comorbidities. We chose age- 
and sex-matched controls randomly from the cohort. These samples 
were chosen for a currently ongoing case–control study of VTE. DNA 
and protein levels were ascertained from the blood collected in 1994.
For this specific study, blood and nonfasting serum samples 
were collected from 330 healthy individuals (166 males and 164 fe-
males) aged 45 to 75 years (Table I in the Data Supplement). There 
were 196 individuals diagnosed with VTE between the study entry 
(1994–1995) and the 18-year follow-up period (2013) and 134 con-
trols without development of VTE during this period. Aspirin usage 
and other medication information were not collected for the Tromsø 
study. DNA was isolated from the blood for genotyping, and serum 
samples were used to assay protein levels. The regional committee 
for medical and health research ethics in North Norway approved the 
study, and all participants gave informed written consent.
Protein Quantification
Protein levels were quantified using the same methods and at the same 
time as our previous MI study,10 but the samples from people who 
went on to develop VTE were not included in that study. Briefly, the 
literature was searched to create a list of >900 cardiovascular-related 
proteins that might be potential biomarkers for MI and atherosclerosis. 
This list was then prioritized to 165 candidate proteins, of which 51 had 
sufficient commercially available reagents (2 antibodies and purified 
protein for control) in order for Tethys Bioscience, Inc (Emeryville, 
CA) to perform successful sandwich enzyme-linked immunosorbent 
assays (Methods section and Table II in the Data Supplement). All 
protein levels were quantile normalized and mapped to the normal dis-
tribution using qnorm in R, and significance was tested using Z scores.
Variant Identification and Annotation
Genotypes were determined using exome sequencing (n=243) or 
exome genotyping arrays (n=87). Sequences were mapped and called 
using the Burrows-Wheeler Aligner11 and Genome Analysis Toolkit,12 
imputed to the 1000 Genomes Project13 using Beagle,14 and function-
ally annotated for predicted effect and regulatory regions (Methods 
section in the Data Supplement).
Statistical Analysis
Associations were performed using the Efficient and Parallelizable 
Association Container Toolbox.15 We used sex, age at study entry, 
body mass index at study entry, genotyping platform, and VTE case–
control status as covariates. Three covariates (age at serum collec-
tion, sex and body mass index at serum collection) were associated, 
respectively, with 10, 10, and 13 of the phenotypes (the 51 protein 
serum levels) when performing linear regressions, defined as having 
a false-discovery rate-adjusted P value of <0.05, and they were in-
cluded for consistency.
For common variants (MAF≥1%), we used the Efficient Mixed 
Model Association eXpedited16 (a mixed model implemented in the 
Efficient and Parallelizable Association Container Toolbox15), using 
q.emmax to test for single-site association. For cis associations, we in-
cluded any imputed common variants located within the interval sur-
rounding and including the gene (±500 kb from transcript start and stop 
positions) that encodes the protein(s) being tested (C3 and C3b share the 
same locus). For cis-acting-in-trans associations, we tested all signifi-
cantly associated common cis variants against each of the other 50 phe-
notypes. For trans associations, we tested the 100 378 common variants 
found in the 50 intervals against each of the 51 phenotypes (Figure 1).
The optimal Sequence Kernel Association Test17 was used to test 
clusters of rare variants (MAF≤5%) for association as implemented 
in the Efficient and Parallelizable Association Container Toolbox, us-
ing the skat-o version of the mmskat test. Rare variants were classi-
fied in 3 ways: (1) MAF≤5%, all rare variants located within the gene 
body and 2kb upstream; (2) deleterious, all rare variants located in the 
gene body and the 2-kb upstream region that were annotated as stop-
gain, stop-loss, start-loss, essential splice site disruption, frame-shift 
causing, or nonsynonymous using Variant Effect Predictor annota-
tions; and (3) Combined Annotation Dependent Depletion (CADD)-
score, all rare variants in the gene or the 2-kb upstream region with a 
Phred-scaled c-score of >10, as determined by Kircher et al.18
We corrected for multiple testing by permuting the phenotype–
genotype relationship 1000× and for each permutation performing all 
variant-phenotype tests for each association type separately (eg, cis, 
cis-acting-in-trans, or trans).19 We obtained the lowest P value from 
each permutation across all phenotypes and created a null distribu-
tion of minimum P values. An association was considered significant 
(family-wise P<0.05) if the nominal P value was <95% of the null 
distribution (Table III in the Data Supplement).
To test for multiple, independent variants in the same locus, the 
top variant was included as a covariate until there was no longer a 
significant association (family-wise P<0.05) detected for that protein.
Power Calculations
We calculated power using an equation from the Abecasis laboratory 
(http://genome.sph.umich.edu/wiki/Power_Calculations:_Quantitative_
Traits) for common variants and the Sequence Kernel Association Test 
R package20 for rare variants. We had 80% power to detect effects (R2) 
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down to 0.113 for the cis, common-variant analysis and effects (β) of 
1.25 for the cis, rare-variant analysis (assuming that 50% of the variants 
are causal), which is comparable to other pQTL studies.4–6,21,22 Further 
details are in the Data Supplement (Methods section, Figures I and II, 
and Table IV in the Data Supplement).
Clinical and Molecular Phenotype Association
Significant pQTLs from this study were queried against the expres-
sion Quantitative Trait Loci (eQTLs) found by Schadt et al23 in liver 
cells and the Gene-Tissue Expression database24 (version 4, build 200, 
accessed at http://www.gtexportal.org/home/) for all tissue types. In 
addition, we determined whether they (or a variant in linkage disequi-
librium [LD]) overlapped any of the variants identified as pQTLs in 
5 similar-sized independent studies that investigated protein levels in 
serum4 or plasma.4–6,22,25 We examined pQTLs for clinical significance 
by determining whether the variant has been previously identified and 
submitted to the Online Mendelian Inheritance in Man,26 the genome-
wide association study (GWAS) Catalog,27 or the Genome-Wide 
Repository of Associations between Single nucleotide polymorphisms 
and Phenotypes v2.0.28 We identified pQTLs that were also significant 
in large meta-analyses of individuals of European descent for CAD 
or VTE. Data on CAD was downloaded from http://www.cardio-
gramplusc4d.org. For this analysis, we only used the results from the 
Coronary Artery Disease Genome wide Replication and Meta-analysis 
(CARDIoGRAM) genome-wide association study29 because these in-
dividuals are of European descent. Data on VTE was shared by the 
International Network against Thrombosis (INVENT Consortium).30
In Vitro Assay of proBNP Cleavage
We obtained native kallikrein from human plasma from EMD-
Millipore (Darmstadt, Germany; cat no. 420307); recombinant 
proBNP from Abcam (Cambridge, Ma; cat no. ab151881); and the 
kallikrein inhibitor, H-D-Phe-Phe-Arg-chloromethyl ketone (PPACK 
II), from Santa Cruz Biotechnology (Dallas, TX; cat no. sc-203215). 
A total of 354 ng (374 nmol/L) of kallikrein was incubated with 80 
ng (606 nmol/L) of proBNP with and without 26.5 ng (36.4 μmol/L) 
of PPACK II for 30, 60, and 90 minutes at 37°C. The reactions were 
stopped by adding 4× lithium dodecyl sulfate sample buffer and di-
thiothreitol, and heating them for 2 minutes at 85°C. The proteins were 
run on a Tricine-SDS–PAGE gel from ThermoFisher (Waltham, MA), 
and either detected using the SilverQuest Silver Staining Kit from 
ThermoFisher or transferred to a polyvinylidene difluoride membrane 
and detected using an anti-BNP antibody from Novus Biologicals 
(Littleton, Co; cat no. NB100-62133) and chemiluminescence.
Results
Study Overview
The subjects were chosen as a substudy from an ongo-
ing case–control study examining the genetics of VTE, and 
includes 196 individuals who developed VTE during the 
18-year follow-up and 134 individuals who did not (Table I 
in the Data Supplement). Serum was assayed for the levels 
of 51 proteins using enzyme-linked immunosorbent assays 
(Table II in the Data Supplement). On average, we obtained 
high-quality protein measurements for 311 individuals per 
phenotype. We investigated whether any of the protein levels 
were associated with VTE case–control status and found no 
significant associations. Knowing that the protein levels were 
not statistically associated with VTE enabled us to combine 
the VTE cases and controls to explore the effects of genetic 
variation on baseline protein levels.
We performed high coverage (≈100×) exome sequenc-
ing on DNA from blood samples for 243 individuals and 
assayed an additional 87 with HumanCoreExome Beadchips. 
We identified 158 137 variants (direct genotyping and impu-
tation) in the 50 intervals that encode the 51 proteins (Table 
V in the Data Supplement). The majority of imputed variants 
were intergenic or intronic because these variants were not 
already captured by the genotyping array or were outside of 
the exome-sequencing target regions (Table VI in the Data 
Supplement). There was an average of 1122 variants per locus 
with the AGER locus having the most variants (3523) and the 
CD40LG locus having the fewest (441; Table II in the Data 
Supplement).
Identifying cis-pQTLs From Common Variants
To identify genetic variation associated with serum protein 
levels, we tested for association between variants within the 
gene’s cis locus and the normalized protein level for each of 
the 51 protein levels, adjusting for sample relatedness and 
population structure using a kinship matrix and including age, 
sex, body mass index, genotype platform, and subsequent 
VTE status as covariates. Because of the high likelihood of 
linkage disequilibrium at the cis loci and slight correlations 
among protein levels, we accounted for multiple testing by 
performing permutations to obtain a family-wise error rate. 
We identified significant associations (adjusted P<0.05, nom-
inal P<6.97×10−7; Table 1; Figure 2) for 13 of the 51 phe-
notypes. To test for multiple, independent associations, we 
performed sequential conditioning on the most highly asso-
ciated variant and found 2 independent cis associations for 
LP(a). Of the 14 cis-pQTLs that we report, we have replicated 
Figure 1. Overview of the 3 stages of association analyses. A, cis: for each of the 51 phenotypes (protein levels), we tested the variants 
located in the cis gene loci for associations with their respective protein level, (B) cis-acting-in-trans: we tested the significant cis-protein 
quantitative trait loci (pQTLs) from stage 1 for trans effects against each of the 50 other protein levels, and (C) trans: we tested all variants 
in the 50 cis loci (C3 and C3b share the same locus) for association with each of the 51 protein levels.
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8 known pQTLs and identified 6 novel pQTLs. The same vari-
ant or a variant in LD (r2>0.5 in EUR) has been previously 
reported for 8 proteins with the same direction of effect that 
we found: AGT,22 C3,5 C3b,5 CHIT1,6 F12,6,25 LBP,6 one of the 
variants for LP(a),31 and MMP332 (Table VII in the Data Sup-
plement). Of the 6 novel pQTLs that we identified, 4 proteins 
have not previously been reported to have a cis-pQTL (a2-AP, 
ANG, KLKB1, and MMP8) and 2 proteins have been previ-
ously associated with a pQTL, but the variant identified here 
is not in LD with the previous variant (KNG125,6 and LP(a)31). 
rs3373402 in KLKB1 was previously reported to affect 
KLKB1 binding with kininogen (KNG1) but did not affect 
KLKB1 levels in plasma33; therefore, although this variant 
has been previously functionally characterized, this is a novel 
pQTL. We annotated the 14 pQTLs for functional effects and 
identified their chromatin state in the tissue where their target 
gene is most highly expressed (Table VIII Data Supplement). 
Ten of the 13 proteins are predominantly secreted by the liver. 
Five of the top variants are missense variants, 3 are in the 
untranslated regions, and 5 lie in predicted regulatory regions 
based on chromatin state annotations. These analyses suggest 
possible mechanisms of action for some of the cis-pQTLs.
Identifying cis-pQTLs From Rare Variation
We next tested whether the combination of multiple rare 
variants at each cis-locus was associated with protein lev-
els. There were 3675 rare variants identified across all 50 
loci. For rare variation association analyses, rare variants are 
grouped according to frequency or function and then jointly 
tested for association. Because functional prediction methods 
vary and it is currently unknown what method is superior,34 
we used 3 different classifications (MAF, Deleterious, and 
Table 1. Significant cis-pQTLs From the Common-Variant Association Analysis










P Value β R2
a2-AP SERPINF2 rs8077638 17 1640793 C/T 0.19 5.4×10−37 <0.001 −1.15 0.42
AGT AGT rs4762 1 230845977 G/A 0.14 4.4×10−22 <0.001 1.08 0.25
ANG ANG rs3748338 14 21167576 A/T 0.11 1.9×10−12 <0.001 0.86 0.16
C3 C3 rs11569415 19 6716279 G/A 0.15 6.9×10−10 <0.001 −0.63 0.13
C3B C3 rs2230199 19 6718387 G/C 0.23 1.2×10−12 <0.001 −0.65 0.16
CHIT1 CHIT1 rs2486951 1 203174921 A/G 0.18 3.7×10−21 <0.001 −1.01 0.26
F12 F12 rs1801020 5 176836532 A/G 0.76 2.5×10−32 <0.001 0.99 0.38
KLKB1 KLKB1 rs3733402 4 187158034 G/A 0.53 4.4×10−12 <0.001 −0.51 0.15
KNG1 KNG1 rs166479 3 186443250 T/C 0.41 1.7×10−10 <0.001 −0.46 0.13
LBP LBP rs2232613 20 36997655 C/T 0.10 2.2×10−22 <0.001 −1.20 0.27
LP(a)* APOA rs41272114 6 161006077 C/T 0.030 3.1×10−8 0.002 −1.27 0.10
LP(a)* APOA rs56393506 6 161089307 C/T 0.083 1.7×10−7 0.011 0.66 0.08
MMP3 MMP3 rs7926920 11 102698724 G/A 0.35 2.4×10−14 <0.001 −0.41 0.17
MMP8 MMP8 rs35231465 11 102584135 G/A 0.036 1.9×10−7 0.012 −1.10 0.09
β indicates effect size of association in standard deviation units per each copy of the alternate allele; Alt, alternate; pQTLs, protein quantitative trait loci; R2, amount 
of phenotypic variation explained by the variant; and Ref, reference.
*LP(a) has 2 independent cis-pQTLs. rs56393506 was identified as an independent pQTL for LP(a) by performing the association analysis using genotypes from the 
top variant (rs41272114) as a covariate.
Figure 2. Association of cis variants with protein levels. Modified Manhattan plot showing the –log10 P values for association between 
variants in each cis locus (interval encoding protein ±500 kb) and the respective protein levels. The red dashed line indicates the study-
wide significant P-value cutoff when only examining cis regions (6.9×10−7) for a family-wise error rate <0.05.
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CADD-score—see Methods section of this article). Across 
all loci, there was a range of 1 to 90 variants used for each 
method, with the MAF method having the most rare variants 
and CADD scores having the fewest. To account for multiple 
testing, we tested all the 3 classifications in each round of per-
mutations to determine the family-wise error rate P-value cut-
off. We performed an optimal Sequence Kernel Association 
Test using the same covariates as for the common-variant asso-
ciation. We identified 8 cis-pQTLs that were significant using 
≥1 classifications (adjusted P<0.05, nominal P<3.72×10−4; 
Table 2; Table IX in the Data Supplement). Of these, cis rare 
variation has been associated with AGER,35 Fetuin A,36 and 
LP(a) levels31; to our knowledge, the other 5 associations are 
novel.
Of the 8 proteins associated with rare variation, 3 were 
also associated with a common pQTL (CHIT1, LP(a), and 
MMP8). For LP(a) and MMP8, a common pQTL (with an 
MAF<5%) was also present on the list of rare variants and 
removal of these from the rare-variant analysis made the rare 
association nonsignificant (CADD nominal P value, 0.148 
and 0.469, respectively). For CHIT1, the common pQTL 
had an MAF of 18% and although not on the list of rare 
variants, when we included this variant as a covariate in the 
rare-variant analysis the association was nullified (nominal P 
value=0.147). These results suggest that the rare variants in 
the CHIT1 locus were associated with CHIT1 serum levels 
because of linkage disequilibrium with the common pQTL. 
Because the driving variant was common, we do not consider 
the CHIT1 association to be valid, resulting in 7 proteins asso-
ciated with rare variants.
Identifying trans-pQTLs
To characterize potential downstream effects of cis-pQTLs, 
we investigated whether any of the common cis-pQTLs might 
also have trans effects (cis-acting-in-trans) on any of the other 
50 protein levels. After permutation to obtain adjusted P val-
ues, we identified 2 cis-acting-in-trans loci, each of which 
was significantly associated with 3 proteins (adjusted P<0.05, 
nominal P<7.29×10−5; Table 3). There was significant over-
lap in the proteins associated with the 2 loci, and the associa-
tions were consistent with known physiological relationships 
between F12, KLKB1, KNG1, and uPAR, and the recently 
reported genetic relationship with NTproBNP37 (Figure 3), 
despite none of the protein levels being strongly correlated 
(Figure 3; Table X in the Data Supplement). We did not 
observe an association between the cis-pQTL for KLKB1 and 
F12 protein levels, despite the known physiological relation-
ships of KLKB1 and F12 (Figure 3). Importantly, the genetic 
associations of KLKB1 and F12 with NTproBNP suggest that 
KLKB1 may physiologically cleave proBNP (the NTproBNP 
precursor). These findings illustrate how genetic variation can 
be used to identify potentially novel physiological relation-
ships among proteins.
We further performed a full pairwise association (trans) 
between any of the variants located in the 50 regions encod-
ing the proteins used in this study and all 51 protein levels. 
After permutation adjusting (adjusted P<0.05, nominal 
P<1.25×10−8), we did not find any additional trans associa-
tions and none of the cis-acting-in-trans associations remained 
significant; however, 11 of the 14 cis associations remained 
significant.
Using a similar approach to the common variants, we tested 
if any of the rare variant cis-pQTLs were associated with any 
of the other 50 protein levels and did not observe any signifi-
cant associations (adjusted P<0.05, nominal P<5.30×10−5). In 
addition, we tested all 50 cis regions against all 51 protein lev-
els in a pairwise manner, but did not identify additional asso-
ciations (adjusted P<0.05, nominal P<9.21×10−6), although 4 
of the 8 rare cis associations were still significant at the more 
stringent threshold.
Role of Kallikrein in proBNP Maturation
We experimentally tested the cis-acting-in-trans associations 
suggesting that kallikrein (KLKB1) may physiologically 
cleave proBNP. ProBNP is produced as a propeptide that 
may be cleaved intracellularly into BNP and NTproBNP, 2 
biomarkers for heart failure,38 before being secreted by car-
diomyocytes in response to cardiac stress. Intracellularly, it is 
thought that furin or corin cleave proBNP,39 but it is unclear 
which enzyme cleaves proBNP extracellularly when it is 
secreted intact.40 To test whether kallikrein can cleave proBNP 
in vitro, we incubated increasing concentrations of kallikrein 
Table 2. Rare Variant cis-pQTLs That Are Significant Using At Least 1 of the 3 Grouping Methods
Protein
MAF≤5% Deleterious CADD10
Nominal P Value Adjusted P Value Nominal P Value Adjusted P Value Nominal P Value Adjusted P Value
AGER 3.2×10−4 0.041 0.003 n.s. 0.006 n.s.
CD40L 0.042 n.s. 9.8×10−5 0.009 0.003 n.s.
CHIT1* 4.3×10−8 <0.001 0.108 n.s. 0.127 n.s.
Fetuin A 2.5×10−4 0.026 1.5×10−5 0.002 2.4×10−6 <0.001
LP(a) 1.1×10−5 0.002 2.6×10−8 <0.001 4.4×10−7 <0.001
MMP8 0.247 n.s. 7.7×10−4 n.s. 6.3×10−6 0.002
TAFI 0.014 n.s. 5.2×10−5 0.003 0.002 n.s.
TIMP4 0.050 n.s. 2.4×10−4 0.026 1.7×10−4 0.018
n.s. indicates not significant; and pQTLs, protein quantitative trait loci.
*Not significant after adjusting for the common pQTL (rs2486951).
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(74.8, 374, 748, and 1497 nmol/L) with proBNP for 1 hour 
at body temperature (37°C) and saw progressive depletion 
of proBNP levels (Figure IV in the Data Supplement). This 
depletion was prevented with the addition of PPACK II, a kal-
likrein-specific inhibitor. From this, we chose to incubate 374 
nmol/L of kallikrein with proBNP for 30, 60, or 90 minutes 
and again, we saw that the levels of proBNP decreased (Fig-
ure 4). These results suggest that kallikrein has the ability to 
cleave proBNP in vivo.
Annotation of pQTLs Using Existing Databases and 
GWAS
We investigated whether the 14 common pQTLs that we iden-
tified were reported as eQTLs in the Gene-Tissue Expression 
database (ref 24) or identified in the liver eQTL dataset from 
Schadt et al.
23
 In the Gene-Tissue Expression database, the AGT 
pQTL was identified as an eQTL in 10 tissues (P values from of 
2.0×10−6 to 1.3×10−33), the CHIT1 pQTL is an eQTL in whole 
blood (P value 4.2×10−8), the F12 pQTL is an eQTL in liver (P 
value 2.3×10−10), and the pQTL in the SERPINF2 locus (a2-
AP protein) is an eQTL in 6 tissues (P values from 5.3×10−7 to 
8.8×10−18). In addition, the pQTLs for a2-AP, AGT, CHIT1, F12, 
KLKB1, and MMP3 were also identified as eQTLs for other 
nearby genes. In the Schadt et al’s data set rs3748338 in the ANG 
locus is in LD (r2=0.24) with an eQTL for ANG (rs8008440). 
Thus, of the 14 common pQTLs, 2 have previously been iden-
tified as an eQTL for the cis gene, 3 as an eQTL for both the 
cis gene and other nearby genes, and 3 as an eQTL for nearby 
gene(s).
We also looked up whether there are any known disease 
associations with the 14 pQTLs that we identified using the 
GWAS catalog.27 the Genome-Wide Repository of Associations 
between Single nucleotide polymorphisms and Phenotypes,28 
and the Online Mendelian Inheritance in Man26 (Table VII 
in the Data Supplement). The 8 known pQTLs along with 
the kallikrein pQTL are associated with a variety of pheno-
types, including age-related macular degeneration (C3b), acti-
vated partial thromboplastin times (F12), serum metabolites 
(KLKB1), binding of LBP to lipopolysaccharide (LBP), and 
plasma plasminogen levels (LP(a)). In total, 9 pQTLs have 
been associated with 17 disease or physiological phenotypes.
Finally, to investigate whether the pQTLs identified here 
are associated with VTE or CAD, we examined the results of 
2 previously published meta-analyses. The INVENT30 study 
is a large meta-analysis of 7507 cases and 52 632 controls to 
identify variants associated with VTE. The CARDIoGRAM29 
study is a large meta-analysis of 22 233 cases and 64 762 
controls designed to identify variants associated with CAD, 
which is predominantly composed of MI. Of 14 common 
pQTLs, 10 (71.4%) could be tested in the INVENT and 
CARDIoGRAM datasets (Table XI in the Data Supplement). 
The KLKB1 pQTL (rs3733402) is significantly associated 
with VTE; however, this association becomes nonsignificant 
when the analysis is conditioned on the top 6 SNPs associated 
with VTE from the literature. The KLKB1 pQTL (rs3733402) 
is also nominally associated with CAD (P=0.0086). The 
KNG1 pQTL (rs166479) had a nominal P value of <0.05 
in the INVENT consortium. Although one of the pQTLs 
for LP(a) (rs41272114) has previously been associated with 
CAD,31 it was not present in either data set. In addition, 
among the 17 protein biomarkers that we previously identi-
fied as being associated with the first MI,10 we identified com-
mon cis-pQTLs for 6 (C3, C3b, KLKB1, LP(a), MMP3, and 
MMP8) and rare cis-pQTLs for 5 (LP(a), MMP8, TAFI, and 
TIMP4). Although we found pQTLs for these MI biomarkers, 
they were not associated with CAD in the CARDIoGRAM 
study, which could indicate that the biomarkers are not caus-
ally related to CAD, but may be a result of the relatively small 
sample size in the GWAS compared with typical Mendelian 
Table 3. cis-pQTLs That Also Act As trans-pQTLs
Variant Protein Nominal P Value Adjusted P Value β R2
rs1801020 in the F12 locus F12 2.5×10−32 <0.001 0.985 0.382
KLKB1 5.4×10−8 <0.001 −0.488 0.092
KNG1 1.1×10−7 <0.001 −0.479 0.097
NTproBNP 1.2×10−5 0.002 −0.380 0.061
rs3733402 in the KLKB1 locus KLKB1 4.4×10−12 <0.001 −0.506 0.152
KNG1 5.2×10−5 0.034 −0.309 0.049
NTproBNP 4.2×10−8 <0.001 −0.393 0.098
uPAR 4.4×10−8 <0.001 −0.401 0.097
β indicates effect size of association in standard deviation units; pQTLs, protein quantitative trait loci; and R2, amount of phenotypic 
variation explained by the variant.
Figure 3. Schematic diagram showing proteins with identified 
trans associations and their nominal associations with variants 
in F12 and KLKB1. Previously known (solid) and proposed in this 
study (dashed) cleavage reactions are represented with arrows. 
Nominal P values for the associations between protein levels and 
rs3733402 in the KLKB1 locus and rs1801020 in the F12 locus 
are shown, respectively, in orange and purple boxes next to the 
protein of interest.
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randomization studies. Thus, although CAD and VTE were 
not significantly associated with pQTLs, these loci could be 
used in further larger studies to elucidate functional mecha-
nisms underlying disease.
Discussion
Using a combination of exome sequencing and exome 
arrays in 330 individuals, we identified 27 genetic associa-
tions between pQTLs and the serum levels of 20 proteins: 
14 associations with common variation in cis, of which 6 are 
novel and have not been previously reported; 7 associations 
with rare variants in cis, of which 4 are novel; and 6 associa-
tions in trans. Ultimately, 15 proteins were associated with 
single sites and 5 were associated with rare variants. The 
strongest associations were identified for cis variation near 
the gene locus, but by directly testing the cis-pQTLs, we 
also identified 2 that acted in trans. Despite the limitations 
of our study (including a relatively small sample size and 
lack of a formal replication cohort), the presence of robust 
associations suggest that exome analysis is an effective tool 
to identify genetic variation associated with serum protein 
levels and that larger sample sizes would likely capture 
additional trans effects.
This is the first study, to the best of our knowledge, that 
uses exome data to investigate the effects of both common 
and rare variation on more than 50 protein levels; and thus, 
it provides insight into rare variant association methods. For 
rare-variant analysis, we used 3 different methods for group-
ing variants within a gene and accounted for the additional 
testing through permutation. Some associations were consis-
tent across all the 3 methods, such as LP(a), which carried a 
large number of variants (Table IX in the Data Supplement) 
and for which rare variation has previously been associated 
with the protein level in the blood.41 Others were only sig-
nificant in 1 test, such as MMP8 when variants were grouped 
based on CADD score, which could be because of few vari-
ants with weak effects and would benefit from larger sample 
sizes to include more predicted functional sites. Variants with 
an MAF between 1% and 5% were tested in both the com-
mon- and rare-variant analyses. In 2 cases (LP(a) and MMP8), 
adjusting for the top common pQTL (with an MAF<5%) nul-
lified the association. In addition, for CHIT1, common varia-
tion (MAF>5%) was associated with rare variants through 
cryptic LD and adjusting for the common variant also nulli-
fied the association. These data suggest that significant com-
mon and rare single sites may drive gene-based rare variant 
associations.
Of the 14 common pQTLs, 4 are missense variants in 
the relevant gene. Of the 10 other variants, 3 are intronic, 
2 are in the exons of nearby genes, and 5 lie in regions that 
are predicted to have regulatory functions, such as interrupt-
ing protein-binding sites or splicing (Table VIII in the Data 
Supplement). Analysis of the function of sequences harbor-
ing the pQTL can elucidate the mechanism of the variant. For 
example, it has been shown that rs1801020 in the 3′ untrans-
lated region of the F12 locus prevents translation of F12.42 
The mechanisms of the other 4 regulatory pQTLs are not 
yet understood, but the results shown here point to plausible 
mechanisms. For instance, ANG and RNASE4 are isoforms of 
the same gene with different functions and differential expres-
sion patterns that are influenced by CTCF.43 The ANG pQTL 
is in the last exon of RNASE4, near a CTCF-binding site that 
affects isoform expression levels.43 This, and other potentially 
regulatory pQTLs, could be functionally tested using in vitro 
and in vivo assays for changes in gene or isoform expression. 
Thus, although we focused on exome sequences to generate 
genotypes for this analysis, imputation enabled us to identify 
many pQTLs with predicted regulatory effects.
pQTLs can be used to understand the relationship between 
proteins and disease, either through tracing molecular impacts 
through pathways or through studies of Mendelian ran-
domization. By examining potential trans associations with 
cis-pQTLs, we recapitulated known and recently reported 
relationships between these proteins. The relationships 
between F12, kallikrein, and kininogen comprise the start of 
the intrinsic coagulation pathway,44 the association between 
kallikrein and uPAR has been previously explored,45 and the 
genetic relationship between kallikrein and NTproBNP was 
identified in a recent GWAS.37 We show that kallikrein is 
able to cleave proBNP in vitro using purified reagents, sug-
gesting that extracellularly, kallikrein could be responsible 
for cleaving proBNP into NTproBNP and BNP, although 
further experiments are necessary to verify that this reaction 
occurs naturally in plasma. We also identified 17 reported dis-
ease and physiological phenotype associations with 9 of the 
pQTLs (8 previously known and 1 novel). Interestingly, 5 of 
the 6 novel pQTLs were not implicated in GWAS studies. This 
could reflect a bias in GWAS phenotypes studied or candidate 
proteins chosen for pQTL studies and supports further work 
identifying downstream effects of these loci. We observed a 
nominal association between KLKB1 and CAD, which we 
previously identified as a biomarker for MI, supporting fur-
ther examination of this relationship in larger studies. Overall, 
these findings support the use of pQTLs to identify molecular 
Figure 4. Kallikrein cleaves proBNP in vitro. A, A silver stain of 
recombinant proBNP and kallikrein incubated together for 30, 60, 
and 90 min with and without a kallikrein-specific inhibitor (PPACK 
II) and (B) a western blot of an identical experimental setup using 
an anti-BNP antibody. The silver stain binds all protein present 
and is a more sensitive procedure than using the anti-BNP anti-
body for the Western blot. We think that this explains why the 
amount of proBNP in the +/+/− wells visually seems to be differ-
ent between the silver stain and Western blot.
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and phenotypic effects of proteins and help to elucidate under-
lying mechanisms of disease.
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CLINICAL PERSPECTIVE
Cardiovascular diseases, including coronary artery disease and venous thromboembolism, are the leading cause of death 
worldwide. Biomarkers are important tools to diagnose or measure risk of disease, but the causal relationship between bio-
markers and diseases is often not clear. Genetic variants that affect levels of protein biomarkers could be used to examine 
causal relationships between biomarkers and diseases and to provide mechanistic insight into disease. In this study, we 
investigated whether genetic variants were associated with the levels of 51 serum proteins, 17 of which we had previously 
identified as predictors for myocardial infarction in the Tromsø Study. We analyzed genotype data from exome sequencing 
and exome arrays and investigated whether common and rare genetic variation located near the gene (cis) that coded for 
each protein was associated with protein levels. We identified 13 proteins associated with common cis variants and 7 proteins 
associated with rare cis variation; 8 of these proteins we had previously identified as biomarkers. To identify pathway-level 
regulation, we tested whether these significantly associated cis variants were also associated in trans with the levels of the 
other 50 proteins in this study. We identified that genetic variation affecting the levels of kallikrein, a protease involved in 
coagulation, also affect the levels of NTproBNP, a known biomarker for heart failure. We experimentally show that kallikrein 
can cleave proBNP into NTproBNP and BNP. Our study shows that identifying genetic variants that affect protein levels can 
provide novel insights and expand our knowledge of the mechanisms of disease.
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Protein Assay  
Protein levels were determined using ELISAs and performed by Tethys Biosciences, Inc 
(Emeryville, CA), as previously reported1. Normal Human Serum from VWR (Radnor, PA), a 
pool made from 10-16% of Tromsø study samples, and dilution buffer were used as controls. 
Each anti-protein antibody was either directly conjugated to an AlexaFluor 647 or was 
biotinylated and detected with a streptavidin-conjugated AlexaFluor 647. Each protein 
underwent 8 serial dilutions. All samples were performed in triplicate. The eight-point standard 
curve was measured in six replicates per plate. The AlexaFluor 647-labeled antibodies were 
detected using the Erenna System (Singulex, Inc., Alameda, CA). Emission from each labeled 
antibody is measured with a photon detector. The photon detector transmits an electronic pulse 
for each photon detected, and pulses are counted in 1-ms bins. Binned pulses that exceed a six 
standard deviation threshold above background are counted. Pulses are recorded as 
photons/minute. For each protein, it must be detected in >70% of samples, there must be more 
than 2 logs of standard curve linear range in the ELISA, and there was less than 20% of variance 
between within-plate replicates for the assay to be considered successful. 
Variant Identification and Annotation 
Genotypes were determined using either the Illumina Infinium HD HumanExome BeadChip 
(N=87) or whole-exome sequencing (N=243) using Agilent SureSelect 50 Mb or V4 capture kits 
and Illumina TruSeq paired-end 100bp cluster kits. Sequence reads were mapped to the reference 
human genome (hg19) using BWA (version 0.7.10-r789) with default parameters and then 
2 
processed using Picard (version 1.115, tool Mark Duplicates) 
(http://broadinstitute.github.io/picard) and GATK (version 3.3-0, tools RealignerTargetCreator, 
IndelRealigner, BaseRecalibrator, PrintReads, and HaplotypeCaller). We previously showed that 
the concordance of the exome sequencing and array genotyping data used in this study is 
99.33%2, therefore we felt confident that we could combine the genotypes from both platforms. 
Using the array data or information from both on and off-target reads3 from the sequencing data, 
genotypes were imputed to the whole genome using Beagle (version 4.0, r1398) and haplotypes 
from unrelated individuals from the European (EUR) and East Asian (EAS) superpopulations of 
the 1000 Genomes Project Phase 34 for sites with a combined MAF >1%. Due to the difference 
in coverage and imputation quality between sites that were exome sequenced or assayed by 
array, we only used sites that had a call rate of >90% in their respective datasets, and then added 
in additional imputation sites passing QC thresholds (allelic r2 of  >0.3). These two datasets were 
combined to get a final VCF with imputed and genotyped sites for both exome sequenced and 
exome genotyped individuals. Because the Tromsø Study is a population-based cohort study, it 
naturally includes some proportion of related individuals. Of the 330 individuals assayed, 20 
were related to another individual in the study at an identity-by-descent value of 0.1 for exome 
sequenced individuals or 0.2 for arrayed individuals, based on genome-wide data.  
 All significant common variants were annotated for functional effects using variant effect 
predictor (VEP)5, RefSeq genes, the hg19 reference genome, GeneVisible 
(http://genevisible.com/search) and ROADMAP6 data of the 28-state chromHMM for Liver 
(E066), HepG2 (E118), and Monocyte (E029) cells. All rare variants (MAF≤5%) were annotated 




Our power to detect causal variants of varying effect sizes was determined using an equation 
from the Abecasis laboratory 
(http://genome.sph.umich.edu/wiki/Power_Calculations:_Quantitative_Traits) for common 
variants and the SKAT R package7 for rare variants. Power for the common variant analyses was 
calculated using a sample size of 300 individuals, a phenotypic variance (R2) from 0.0 to 1.0, and 
alpha levels of 6.97 x 10-7 for the cis association, 7.29 x 10-5 for the cis-acting-in-trans analysis, 
and 1.25 x 10-8 for the trans analysis (Supplemental Table 4, Supplemental Figure 1). Power for 
the rare variant analysis was calculated using a sample size of 300 individuals, an effect size (β 
in standard deviations) from 0.0 to 5.0, the default haplotypes (European) for the SKAT package, 
a causal MAF cutoff of 5%, a sampling subregion length of 3kb, and alpha levels of 3.72 x 10-4 
for the cis association, 5.30 x 10-5 for the cis-acting-in-trans, and 9.21 x 10-6 for the trans 
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Supplemental Table 1: Cohort statistics 
 





N Exome Arrayed 
VTE Controls 



























N, number  
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Supplemental Table 2: The fifty-one proteins and 50 loci (C3 and C3b derive from the same gene and locus, but are considered two 
proteins here) used in this study. 
 
Protein 


























ADIPOQ 3 186060462 187076252 766 329 6.81 0.74-99.32 ug/mL 
AGER 
 
advanced glycosylation end 
product-specific receptor 
 








































C3 19 6177845 7220662 1714 284 233.77 71.76-631.00 mg/mL 
C3b 
 
complement component C3b 
 
C3 19 6177845 7220662 1714 301 2.95 1.05-16.21 ug/mL 
CCL5 
 
C-C motif chemokine 5 
 
CCL5 17 33698495 34707377 923 328 155.92 7.77-759.97 ng/mL 
CD14 
 
monocyte differentiation antigen 
CD14 
 
CD14 5 139511312 140513286 1104 328 244.71 76.28-739.07 ng/mL 
CD163 
 
scavenger receptor cysteine-rich 
type 1 protein M130 
 

























CTSG 14 24542723 25545466 1539 330 37.26 6.88-186.27 ng/mL 
CXCL10 
 
C-X-C motif chemokine 10 
 





DCN 12 91039034 92073359 128 303 13.47 6.00-31.13 ng/mL 
DPP4 
 
dipeptidyl peptidase 4 
 
DPP4 2 162348754 163431052 530 328 992.83 225.56-5879.35 ng/mL 
F12 
 
coagulation factor XII 
 









ferritin heavy chain 
 





HP 16 71588507 72594955 1000 301 799.22 0.06-4090.92 ug/mL 
HSPA1B 
 
heat shock 70kDa protein 1B 
 
HSPA1B 6 31295511 32298031 3372 303 4.05 0.90-62.02 ng/mL 
ICAM1 
 
intercellular adhesion molecule 1 
 









































MPO 17 55847216 56858296 1116 303 60.57 12.77-271.17 ng/mL 
NTproBNP 
 
n-terminus pro-brain natriuretic 
protein 
 
NPPB 1 11417520 12418992 1380 303 0.30 0.02-6.38 ng/mL 
PAI-1 
 
plasminogen activator inhibitor 1 
 





REN 1 203623943 204635465 1018 329 0.63 0.05-3.33 ng/mL 
SHBG 
 
sex hormone-binding globulin 
 















THBS4 5 78831169 79879107 810 303 2.79 0.16-192.66 ug/mL 
TIMP1 
 
metalloproteinase inhibitor 1 
 
TIMP1 X 46941689 47946190 501 328 61.42 7.27-176.27 ng/mL 
TIMP4 
 
metalloproteinase inhibitor 4 
 
TIMP4 3 11694567 12700851 573 302 5.20 1.88-18.00 ng/mL 
TNFRSF11B 
 
tumor necrosis factor receptor 
superfamily member 11B 
 
TNFRSF11
B 8 119435795 120464383 175 328 49.80 11.71-152.77 ng/mL 
TNFRSF1B 
 
tumor necrosis factor receptor 
superfamily member 1B 
 
TNFRSF1B 1 11727059 12769277 1355 328 19.79 7.56-49.06 ng/mL 
uPAR 
 
urokinase plasminogen activator 
surface receptor 
 
PLAUR 19 43650246 44674498 1362 303 1.73 0.54-4.91 ng/mL 
VCAM1 
 
vascular cell adhesion protein 1 
 





Supplemental Table 3: Number of tests performed for each type of association analysis and the P-value cutoffs using Bonferroni 
correction or permutations for a FWER < 0.05. 
 




Common, single site 



























Supplemental Table 4: Amount of phenotypic variance explained (R2) and effect size (β) detected for the various analyses when 
























Alpha Effect Size (β) 












9.21 x 10-6 1.0 












9.21 x 10-6 1.75 
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Exome Sequenced (N = 243) 
 












153,510 58,758 158,137 
 






















% of total Exome 
Sequenced variants that 
were imputed 
% of total Exome 

























3378 1568 313 380 8.5% 19.5% 
 
Coding sequence indels 
 
192 0 16 34 7.7% 100.0% 
 
start or stop related 
variants 
 
72 25 7 8 8.9% 24.2% 
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Supplemental Table 7: Reported disease associations of the significant cis-pQTLs. 
 









Schadt eQTL GTEx eQTL Genome-wide associations OMIM 
AGT rs4762 1 230845977 Kim8 (yes)  
 
AGT sun-exposed skin, transformed 
fibroblasts, non-exposed skin, 
subcutaneous adipose, lung, colon, 
breast, testis, esophagus (2.0x10-6 to 
1.3x10-33); RP11-99J16_A.2 
transformed fibroblasts, sun-exposed 
skin, subcutaneous adipose 
(6.0x10-10 to 1.0x10-14) 
 
 
in LD with rs699 and rs5051  
(r2 = 0.24, D' = 1) which are 
associated with hypertension, 
lower promoter activity and  
transcription amount 
ANG rs3748338 14 21167576 novel 
 
rs8008440 (r2=0.24) 
-log10p = 5.7144 
 
   
C3 rs11569415 19 6716279 Johansson
9 
(yes)    
 
in LD with rs2230199 (r2 = 0.98, 
D’ = 0.99) which is associated 
with age-related macular 
degeneracy 
 
C3 rs2230199 19 6718387 Johansson
9 




age-related macular degeneracy, 
slow and fast in electrophoresis, 
kidney production of C3 
 




CHIT1 whole blood (4.2x10-8); 




F12 rs1801020 5 176836532 Liu
11 
(yes)  
F12 liver (2.3x10-10); MXD3  
esophagus (4.2x10-6) 
 
F12 levels, protective effect on 
acute coronary syndrome in 
people with stable CAD, 
activated partial thromplastin 




KLKB1 rs3733402 4 187158034 novel  
F11 artery, esophagus, brain, 
 and muscle (1.8-7.0x10-6) 
 
B-type natriuretic peptide, 
midregional-proadrenomedullin 
and C-terminal-pro-endothelin-
1, serum metabolite levels 
 
PKD Sedi is two mutations 
(compound heterozygosity  
with rs121964952) that  
reduce binding to HMWK 
KNG1 rs166479 3 186443250 novel   
 




LBP rs2232613 20 36997655 Lourdusamy
10 
(yes)   
 
reduced binding capacity for 
LPS, homozygous has low 
serum concentrations, protease 
cleavage site, carriers have 
cleaved LBP which doesn't 









  plasma plasminogen levels  




    




MMP1 transformed fibroblasts  
(6.8x10-9); WTAPP1 transformed 
fibroblasts, testis (1.9-8.0x10-7) 
 
Serum MMP-1 levels  
MMP8 rs35231465 11 102584135 
 
novel 
     
SERPINF2 rs2070863 17 1648502 novel  
 
SERPINF2 skeletal muscle,  
sun-exposed skin, subcutaneous adipose, 
transformed fibroblasts, esophagus, testis 
(5.3x10-7 to 8.8x10-18); WRD81 
esophagus, sun-exposed skin, breast  





Supplemental Table 8: Functional annotations of the 14 significant cis-pQTLs using GeneVisble, variant effect predictor (VEP) and 
ROADMAP data of the 28-state chromHMM for Monocyte (E029), Liver (E066) and HepG2 (E118) cells. 
 








ROADMAP VEP Annotations 




missense variant (AGT); 
TF binding site variant (Nrsf) 
 




quiescent missense (RNASE4) 
LP(a) APOA rs41272114 6 161006077 liver quiescent quiescent quiescent 
 
splice donor variant (APOA) 
 
LP(a) APOA rs56393506 6 161089307  quiescent quiescent quiescent 
 
upstream gene variant (APOA); 
regulatory region variant 
(CTCF binding site) 
 




C3b C3 rs2230199 19 6718387 liver quiescent downstream promoter TSS 2 
downstream 
promoter TSS 2 
 
missense (C3); TF binding 
site variant (Egr1) 
 
CHIT1 CHIT1 rs2486951 1 203174921 macrophage quiescent quiescent quiescent 
 
regulatory region variant 
(promoter flanking region); 
intergenic 
 






start site 5' UTR variant (F12) 












quiescent missense (LBP) 




MMP8 MMP8 rs35231465 11 102584135 bone marrow quiescent quiescent quiescent 
 
Stop gain (MMP8); 3' UTR 
variant (MMP8) 
 






synonymous variant (WDR81); 
upstream gene variant; 




Supplemental Table 9: List of rare variants that comprise each significant rare cis-pQTL association and their P-values from the 
single-site associations. An X means that the variant was used in the indicated clustering method. Gray regions mean that the 
collapsed region was not significant using that clustering method. 
 


























 6 32147157 rs41268928,rs116420335 G/C 0.03465 0.0005482 X   
 6 32148724 rs41270464,rs114878357 C/T 0.04125 0.8907 X   
 6 32148814 . GGGTTATACAGGAGAGA/G 0.0022 NA X   
 6 32148909 rs201575255 CTG/C 0.00165 NA X   
 6 32149065 rs181811810 C/T 0.00441 NA X   
 6 32149140 rs3176931 C/T 0.00658 NA X   
 6 32149471 rs114564020 G/A 0.0022 NA X   
 6 32149571 . C/A 0.01322 0.01551 X   
 6 32149801 rs9391855,rs116515025 C/T 0.02211 0.03112 X   
 6 32149883 rs204996,rs116334026 C/T 0.0297 0.1413 X   
 6 32150047 rs77170610 C/T 0.00704 NA X   
 6 32150107 . TGAGGCCCTATCTCAGG/T 0.0022 NA X   
 6 32150303 rs144335694 T/C 0.0022 NA X   
 6 32150523 . T/C 0.0022 NA X   
 6 32150872 . G/A 0.0022 NA X   
 6 32151443 rs2070600,rs114177847 C/T 0.0396 0.001871 X   
 6 32151458 rs80096349,rs116828224 G/A 0.00165 NA X   
 6 32151539 . G/A 0.0022 NA X   
 6 32151882 rs115111668 C/T 0.0022 NA X   
Fetuin A 3 186329282 rs111451953 G/A 0.03084 0.4621 X   
 3 186330883 . G/A 0.00441 NA X   
 3 186331119 . T/A 0.00441 NA X   
 3 186331138 rs150486317 C/T 0.01159 0.5768 X X  
 3 186331245 rs190631595 G/T 0.0022 NA X   
 3 186331298 . A/C 0.00231 NA X   
 3 186331299 . G/C 0.00231 NA X   
 3 186333378 . C/A 0.0022 NA X   
 3 186334343 rs79747711 T/G 0.00441 NA X   
 3 186334932 . A/G 0.0022 NA X   
 3 186335056 rs140827890 G/A 0.00661 0.5564 X X X 
 3 186335248 rs144616056 G/A 0.01762 0.5311 X   
 3 186337746 rs149819140 T/C 0.0022 NA X   
 3 186337871 rs184392275 G/A 0.0022 NA X   
 3 186338320 . T/G 0.0022 NA X   
 3 186338540 rs35799453 T/C 0.00441 NA X   
15 
 3 186338564 rs35457250 C/T 0.01821 1.48E-06 X X X 
 3 186338869 rs11540663 C/T 0.01542 0.9813 X   
CD40LG X 135741275 . G/A 0.0022 NA  X  
 X 135741443 rs148594123 G/A 0.0165 0.001338  X  
CHIT1 1 203183825 rs2015402 G/A 0.04846 0.2873 X   
 1 203184018 rs946849 T/C 0.04846 0.2873 X   
 1 203184924 rs80241012 G/A 0.02643 0.1151 X   
 1 203185118 rs17532442 C/T 0.03744 0.2581 X   
 1 203186420 . A/C 0.01106 0.667 X   
 1 203186666 rs41308417 C/G 0.02212 0.6183 X   
 1 203188379 . CCCACTGGTTGTCCCGGAAGATGTAGGGCA/C 0.00661 0.02734 X   
 1 203189093 rs76499133 C/T 0.03111 0.02956 X   
 1 203189350 rs74969659 G/A 0.03304 0.2992 X   
 1 203189634 rs2486959 A/G 0.04626 3.46E-13 X   
 1 203191527 rs56152830 C/T 0.01322 0.4565 X   
 1 203191994 rs7512820 G/A 0.00889 0.3586 X   
 1 203192424 rs181385947 G/A 0.02643 0.9288 X   
 1 203192518 . G/A 0.00661 0.9764 X   
 1 203193134 rs2486068 T/G 0.04405 1.32E-09 X   
 1 203194544 rs140940634 C/CATT 0.03965 0.5655 X   
 1 203194548 rs184545416 G/T 0.03965 0.5655 X   
 1 203194688 . C/T 0.00441 NA X   
 1 203194834 rs137852607 C/T 0.0033 NA X   
 1 203195006 rs116389839 G/A 0.01322 0.2128 X   
 1 203195126 rs185483258 C/T 0.00229 NA X   
 1 203195398 rs10920587 C/A 0.00881 0.9725 X   
 1 203195689 rs2486070 G/A 0.04405 9.21E-11 X   
 1 203196479 rs2486071 A/C 0.04626 9.39E-11 X   
 1 203196842 rs56035601 C/T 0.03965 0.5655 X   
 1 203198596 rs72739588 G/A 0.02477 0.2938 X   
LP(a) 6 160952621 rs41266381 A/C 0.00441 NA X   
 6 160952667 rs73012273 C/G 0.01982 0.7021 X   
 6 160952780 rs186413938 C/T 0.0033 NA X X X 
 6 160952816 rs41267807 T/C 0.0132 0.4979 X X X 
 6 160953642 rs41267809 A/G 0.0198 0.01013 X X  
 6 160960892 . AAG/A 0.0022 NA X   
 6 160961137 rs3798220 T/C 0.00828 0.1252 X X X 
 6 160962115 . A/G 0.0022 NA X   
 6 160962151 . T/G 0.0022 NA X X X 
 6 160962185 . A/G 0.00441 NA X   
 6 160962190 . C/A 0.0022 NA X X X 
 6 160962366 . TC/T 0.02535 0.8887 X   
 6 160962368 rs116039216 G/T 0.02546 0.8848 X   
 6 160962370 rs116089584 G/T 0.02804 0.9047 X   
16 
 6 160963576 rs41265940 T/A 0.00221 NA X   
 6 160963648 rs6920765 G/A 0.0022 NA X   
 6 160963964 rs41265934 C/G 0.00441 NA X   
 6 160964135 rs41265930 T/C 0.00661 0.868 X   
 6 160966559 rs139145675 G/A 0.00165 NA X X X 
 6 160968863 rs149574804 C/T 0.01982 0.4082 X   
 6 160968968 rs41264848 G/A 0.0022 NA X   
 6 160969075 rs41264844 C/T 0.03084 0.5789 X   
 6 160969096 rs4708871 C/T 0.02423 0.2038 X   
 6 160969113 rs145989243 G/A 0.0022 NA X   
 6 160971286 rs62441900 C/G 0.03965 0.2143 X   
 6 160973905 rs62441901 C/G 0.03965 0.2143 X   
 6 160976914 . CA/C 0.00221 NA X   
 6 160978270 rs184372256 A/G 0.00442 NA X   
 6 160978686 rs149526393 A/G 0.00441 NA X   
 6 160985107 rs145783310 A/G 0.0495 0.7805 X   
 6 160985438 rs79563112 C/T 0.0495 0.7805 X   
 6 160985526 rs118039278 G/A 0.02632 0.0406 X   
 6 160997118 rs74617384 A/T 0.02632 0.0406 X   
 6 160998052 rs76602267 G/A 0.00441 NA X   
 6 160998143 . C/T 0.0022 NA X   
 6 161005610 rs55730499 C/T 0.02632 0.0406 X   
 6 161005898 . C/T 0.00221 NA X   
 6 161005908 rs41272116 ACTT/A 0.00221 NA X   
 6 161006077 rs41272114* C/T 0.0297 1.05E-08 X X X 
 6 161006084 rs76144756 G/A 0.00441 NA X X X 
 6 161006105 rs41272112 C/T 0.00165 NA X X  
 6 161007647 . G/A 0.0022 NA X   
 6 161010118 rs10455872 A/G 0.01815 0.005497 X   
 6 161010546 rs41267815 G/C 0.00441 NA X   
 6 161011907 rs74334585 C/T 0.01101 0.1663 X   
 6 161012262 rs144958108 A/G 0.00667 0.8523 X   
 6 161015301 rs41271036 A/G 0.01101 4.23E-06 X   
 6 161016414 . A/G 0.0022 NA X   
 6 161020526 rs41270998 A/G 0.0022 NA X   
 6 161020532 . G/A 0.00661 0.417 X  X 
 6 161021800 . G/T 0.00221 NA X   
 6 161022107 rs41259144 C/T 0.00662 0.003408 X X X 
 6 161022108 rs186072375 G/T 0.0022 NA X  X 
 6 161025782 . G/T 0.00455 NA X   
 6 161026197 rs117174672 G/A 0.03084 0.2908 X   
 6 161026250 . G/A 0.0022 NA X   
 6 161027256 . A/G 0.00231 NA X   
 6 161027287 . G/C 0.00221 NA X   
 6 161027430 rs144587038 G/T 0.01542 0.1217 X   
17 
 6 161027821 rs75055004 A/T 0.0022 NA X   
 6 161027895 . TA/T 0.00457 NA X   
 6 161032267 rs117949336 C/T 0.00461 NA X   
 6 161032369 rs151298886 C/T 0.00221 NA X   
 6 161032401 rs78893353 G/A 0.01106 0.1991 X   
 6 161032413 . G/C 0.00221 NA X   
 6 161032497 rs112092923 A/G 0.02212 0.09362 X   
 6 161055824 . C/A 0.00243 NA X   
 6 161055876 . C/T 0.00444 NA X   
 6 161055880 . G/A 0.00222 NA X   
 6 161055942 . G/C 0.00441 NA X   
 6 161055968 . C/A 0.0022 NA X   
 6 161055991 . C/T 0.0022 NA X   
 6 161056129 . T/TAGA 0.0022 NA X   
 6 161071476 rs200491482 T/G 0.00165 NA X X X 
 6 161071615 . G/A 0.0022 NA X   
 6 161071638 . T/C 0.0022 NA X   
 6 161087336 rs117643720 T/C 0.0022 NA X   
 6 161087368 . G/A 0.00881 0.06095 X   
 6 161087372 rs181060240 T/C 0.01322 0.03437 X   
MMP8 11 102584135 rs35231465* G/A 0.03642 6.86E-07   X 
 11 102585130 . A/G 0.00224 NA   X 
 11 102586142 rs61753779 A/G 0.00166 NA   X 
 11 102592160 rs11602288 G/A 0.00661 0.7785   X 
 11 102593266 rs112188995 C/T 0.00993 0.1649   X 
TAFI 13 46627762 rs145067962 A/T 0.0066 0.003747  X  
 13 46648069 rs140446990 T/C 0.00495 0.0407  X  
 13 46656619 . C/T 0.0022 NA  X  
TIMP4 3 12195137 . G/C 0.00221 NA  X X 
 3 12195660 rs140022692 G/A 0.01106 0.1126   X 
 3 12198889 . A/G 0.00221 NA  X X 
 3 12200201 . C/T 0.00221 NA  X X 
 3 12200210 . G/A 0.00442 NA  X X 
 3 12200219 . A/G 0.00221 NA  X X 
 3 12200269 . C/T 0.00221 NA   X 
* = variant was tested in both the common analysis and in the rare analysis.
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-0.06 0.20 0.32 0.28 1.0 
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Supplemental Table 11: Lookup of common cis-pQTLs for their associations in the 
CARDIoGRAM and INVENT meta-analyses.  
 









P-value β SE P-value β SE 
a2-AP rs8077638* 17 1640793 C/T 0.3399 0.156 0.017 Not in INVENT 
a2-AP rs8065251* 17 1637458 G/A 0.3552 0.015 0.017 0.3298 -0.028 0.029 
AGT rs4762 1 230845977 G/A 0.5018 -0.143 0.021 0.1694 -0.048 0.035 
ANG rs3748338 14 21167576 A/T 0.4549 0.020 0.027 0.9519 0.002 0.039 
C3/C3b rs2230199† 19 6718387 G/C 0.1045 0.050 0.031 0.7668 0.010 0.034 
CHIT1 rs2486951 1 203174921 A/G 0.7288 -0.006 0.017 0.8562 -0.005 0.028 
F12 rs1801020 5 176836532 A/G 0.5115 -0.016 0.246 0.6957 0.011 0.028 
KLKB1‡ rs3733402 4 187158034 G/A 0.0086 0.040 0.015 8.2x10-12 -0.159 0.023 
KNG1 rs166479 3 186443250 T/C 0.1692 0.020 0.014 0.0436 -0.046 0.023 
LBP rs2232613 20 36997655 C/T 0.3624 0.025 0.028 0.3531 0.050 0.054 
MMP3 rs7926920 11 102698724 G/A 0.1016 0.023 0.014 0.7347 0.008 0.023 
 
Bolded indicates a nominal P-value of <0.05. β, effect size. SE, standard error 
* rs8077638 was not present in the INVENT dataset, so the next most significant variant (rs8065251) was looked up 
in both studies as well. 
† The top variant for C3 (rs11569415) was not present in either CARDIoGRAM or INVENT so the next most 
significant variant (rs2230199) was used. 
‡ The association with VTE was no longer significant after adjustment that included rs4253417. 
No significant variants for LP(a) or MMP8 were present in either study. 
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Supplemental Figure 1: Power to detect common variation pQTLs with varying effect sizes in 
the three stages of analysis. A) Power curve for cis-pQTLs using the permutation cutoff of 
6.91x10-7 as the alpha. B) Power curve for testing the cis-pQTLs acting-in-trans using the 
permutation cutoff of 7.29x10-5 as the alpha. C) Power curve for trans-pQTLs using the 
permutation cutoff of 1.25x10-8. The x-axis is measuring the amount of variance of the 





Supplemental Figure 2: Power to detect rare variation pQTLs with varying effect sizes in the 
three stages of analysis. Effect size is measured in standard deviations (β). The top row assumes 
that all variants have an equal effect and that all variants are causal. The bottom row assumes 
that all variants have an equal effect and that half of the variants tested are causal. A) power to 
detect cis associations, alpha = 3.72 x 10-4; B) power to detect cis-acting-in-trans pQTLs, alpha 
= 5.30 x 10-5; C) power to detect trans associations, alpha = 9.21 x 10-6. The x-axis is measuring 








Supplemental Figure 3: Pearson’s correlation of the protein levels. Dendrogram shows 
clustering based on correlation. Black lines are outlining the proteins identified in the cis-acting-
in-trans analysis: F12, KLKB1, KNG1, NTproBNP, uPAR; corresponding values can be found 




Supplemental Figure 4: Silver stain of proBNP incubated for 1 hour with varying 
concentrations of kallikrein, with and without a kallikrein-specific inhibitor, PPACK II. 
Kallikrein concentrations are 74.8nM, 374nM, 748nM, and 1497nM. The upper bands are the 
light and heavy chains of kallikrein. The lower band is proBNP. 374nM of kallikrein was chosen 
to perform the silver stain and western blot in Figure 4 of the paper. 
 
 
